Supporting · Sub-categories
Drug discovery holds 71% of the value; small molecules and platforms alone 43%
| Sub-category | Startupsall, funded or not | Breakouts$15M+ raised | Scaleups$100M+ raised | $1B+ companieslatest valuation | Combined valuelatest valuations | $1B+ company |
|---|---|---|---|---|---|---|
| AI × materials | ||||||
| Materials discovery platforms | 23 | 3 | 1 | 1 | $3.6B |  |
| Energy and climate materials | 22 | 3 | 0 | 0 | $561M | |
| Chemicals | 6 | 0 | 0 | 0 | $1M | |
| Other advanced materials | 16 | 0 | 0 | 0 | $31M | |
| AI × engineering | ||||||
| Design and simulation software | 30 | 4 | 2 | 1 | $3.8B |  |
| Manufacturing and robotics | 50 | 9 | 0 | 1 | $2.5B |  |
| Energy | 28 | 6 | 1 | 0 | $571M | |
| Chips and electronics | 20 | 3 | 0 | 0 | $526M | |
| Space | 12 | 0 | 0 | 0 | $71M | |
| Mobility | 6 | 0 | 0 | 0 | $40M | |
| Other engineering | 109 | 2 | 0 | 0 | $1.5B | |
| AI × drug discovery | ||||||
| Small molecules and platforms | 208 | 29 | 9 | 1 | $20B |  |
| Oncology | 59 | 22 | 2 | 1 | $4.8B |  |
| Genomics and gene editing | 55 | 20 | 5 | 0 | $4.7B | |
| Diagnostics and imaging | 30 | 8 | 2 | 0 | $1.8B | |
| Proteins and biologics | 15 | 3 | 0 | 0 | $702M | |
| Clinical trials | 10 | 2 | 0 | 0 | $415M | |
30
Source: Dealroom.co, 9 November 2026. 699 European companies in AI × materials, engineering and drug discovery, launched since 2000. Sub-categories from Dealroom sector tags; each company counted once. Breakouts and scaleups by total funding of any type; value = latest valuation as recorded by Dealroom, including estimates.